$-0.29 EPS Expected for Q BioMed Inc. (QBIO) as of July, 18

June 27, 2018 - By Sarah Holford

Q BioMed Inc. (OTCMKTS:QBIO) Corporate Logo

Q BioMed Inc. (OTCMKTS:QBIO)’s earnings report is expected by WallStreet on July, 18, Zacks reports. Analysts predict 0.00 % diference or $-0.29 from the $-0.29 EPS from 2017. 70.59 % negative EPS growth is what analysts predict. $-0.17 earnings per share was reported for last quarter. Ticker’s shares touched $3.42 during the last trading session after 0.29% change.Q BioMed Inc. has volume of 16,791 shares. Since June 27, 2017 QBIO has 0.00% and is . QBIO underperformed the S&P500 by 12.57%.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.The firm is valued at $47.79 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.Currently it has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.